PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
News from the PCSK9 Education and Research Forum

FOURIER and ODYSSEY: Targeting high risk patients

Two recent studies focus on the role of genetic risk scores that could provide improved identification of high-risk patients in order to improve cardiovascular outcomes. Analyses of the FOURIER and ODYSSEY OUTCOMES trials show that those patients with high genetic risk have a high cardiovascular event rate and benefit the most from treatment with a PCSK9 inhibitor.

Read more below

Read more on FOURIER genetic risk score and evolocumab benefit »

Read more on ODYSSEY predicting alirocumab benefit with genetic risk score »


TST trial results: LDL-C <70 mg/dl target optimal

The Treat Stroke to Target trial highlights the superiority of aggressive LDL-C reduction (< 70 mg/dl) over more modest reduction in patients with atherosclerotic cardiovascular disease and stroke. The trial shows that clinicians should aim to reduce LDL-C targets to <70 mg/dl in their patients with atherosclerotic stroke in order to reduce cardiovascular events.

Read the report here »


Don't miss our slide decks focusing on key results and expert analysis from FOURIER and ODYSSEY OUTCOMES and ODYSSEY trials


DOWNLOAD THEM NOW »

Register now at www.pcsk9forum.org to access our new slide deck programme.
PCSK9 App


Education: the primary mission of PCSK9 Forum.

Don’t forget to check back for the latest updates to the PCSK9 Forum educational slide resource programme


Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen The Medicines Company Sanofi
Copyright PCSK9 Forum 2019. Please click here to unsubscribe from future mailings.